{"time_collected":"2023-03-20 17:10:06.812752-04:00","top_headers":[{"heading":"ATNF Lounge Pt. 3","time_posted":"2 years ago"},{"heading":"180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytrenâ€™s Disease","time_posted":"2 months ago"},{"heading":"ATNF on RegSho","time_posted":"2 months ago"},{"heading":"Stock Movement and Daily Volume","time_posted":"2 months ago"},{"heading":"A Bulls-Eye View of ATNF","time_posted":"3 months ago"},{"heading":"Alliance Global Starts 180 Life Sciences at Buy with $4 Price Target 12:15 PM EDT, 10/20/2022","time_posted":"5 months ago"},{"heading":"Trying to clarify situation: Dupuytren's research a success, but FDA/MHRA said they don't see evidence that shrinking/softening nodules will lead to reduced finger contracture, so for now it's considered by FDA/MHRA to be unproven hypothesis. 180LS says \"preparing the evidence\". Cash running low.","time_posted":"9 months ago"},{"heading":"Compare people's stated experiences with the Xiaflex injections into the hand with the experiences of adalimumab. Xiaflex is notorious for negative efffects. The FDA and MHRA are being inconsistent if they approve Xiaflex but not adalimumab injection. I think 180LS will probably make this argument.","time_posted":"9 months ago"}],"subreddits":{},"about":{"header":"About Community","description":"Community of ATNF shareholders.","created":"Created Feb 12, 2021","stats":["1.4k Members","7 Online"]},"other_information":[]}